Click Therapeutics, Inc.

3 articles about Click Therapeutics, Inc.

• Otsuka and Click Therapeutics Announce the U.S. Food and Drug Administration (FDA) Clearance of Rejoyn

  4/1/2024

  Otsuka Pharmaceutical, Co. Ltd. (Otsuka) and Click Therapeutics, Inc., (Click) announce that the U.S. Food and Drug Administration (FDA) has cleared Rejoyn.

• Click Therapeutics and Boehringer Ingelheim Announce FDA Breakthrough Device Designation for Prescription Digital Therapeutic to Treat Negative Symptoms of Schizophrenia

  1/4/2024

  Click Therapeutics, Inc. (“Click”), a leader in Digital Therapeutics™ as prescription medical treatments, today announced that the investigational CT-155 prescription digital therapeutic (PDT), co-developed by Boehringer Ingelheim and Click Therapeutics, has received Breakthrough Device designation from the U.S. Food and Drug Administration (FDA).

• Click Therapeutics Announces Participation in November Investor Conferences

  11/7/2023

  Click Therapeutics, Inc., a leader in Digital Therapeutics™ as prescription medical treatments, announced that Randall Stanicky, Chief Financial Officer, will participate in the following investor conferences this month.